Figure 3.

Application of the lenvatinib prognostic (LEP) index to lenvatinib validation cohort and to patients treated with sorafenib and comparison of the two treatments in the three risk groups identified with recursive partitioning analysis RPA.

(A) Overall survival analysis of Italian patients treated with lenvatinib based on risk groups identified with RPA. (B) Progression-free analysis of Italian patients treated with lenvatinib based on risk groups identified with RPA. (C) Survival analysis of patients treated with sorafenib based on risk groups identified with RPA. (D) Forest plot comparing sorafenib with lenvatinib training cohort (Eastern population). (E) Forest plot comparing sorafenib with lenvatinib validation cohort (Italian population).